LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.

ABSTRACT: Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however, they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade (ICB) treatment choices are lacking. We designed this study to identify blood-based correlates of clinical outcome in ICB-treated patients. We performed immune profiling of 188 ICB-treated patients with melanoma using multiparametric flow cytometry to characterize immune cells in pretreatment peripheral blood. A supervised statistical learning approach was applied to a discovery cohort to classify phenotypes and determine their association with survival and treatment response. We identified three distinct immune phenotypes (immunotypes), defined in part by the presence of a LAG-3⁺CD8⁺ T cell pop

SUBMITTER: Shen R 

PROVIDER: S-EPMC9254663 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature